Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera ...

The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

Objectives (1) Describe how the risk of major adverse cardiovascular events (MACE) in individuals with chronic myeloid leukaemia (CML) has evolved; (2) evaluate the risk of MACE associated with the ...

Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis, psoriasis, ...

Sillajen Inc. has recently presented data regarding their threonine tyrosine kinase (TTK) and Polo-like kinase 1 (PLK1) dual inhibitor BAL-0891 as a therapeutic approach for acute myeloid leukemia ...

Departments of Medicinal Chemistry and Cell & Molecular Biology, Pharmacia Corporation, Kalamazoo, Michigan 49007; Department of Medicinal Chemistry, Biovitrum AB, SE-75182 Uppsala, Sweden; and ...

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline ...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at Goldman ...

Panelists discuss potential changes to clinical pathways for Bruton tyrosine kinase (BTK) inhibitor therapies as a result of ...

The firm will assess irpagratinib plus best supportive care in patients with FGF19-overexpressing advanced liver cancer.